BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 22309595)

  • 21. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
    Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
    Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
    Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK
    Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.
    Wu X; Ge H; Lemon B; Vonderfecht S; Weiszmann J; Hecht R; Gupte J; Hager T; Wang Z; Lindberg R; Li Y
    J Biol Chem; 2010 Feb; 285(8):5165-70. PubMed ID: 20018895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
    Poh W; Wong W; Ong H; Aung MO; Lim SG; Chua BT; Ho HK
    Mol Cancer; 2012 Mar; 11():14. PubMed ID: 22439738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 19 stimulates water intake.
    Ursic-Bedoya J; Chavey C; Desandré G; Meunier L; Dupuy AM; Gonzalez-Dopeso Reyes I; Tordjmann T; Assénat E; Hibner U; Gregoire D
    Mol Metab; 2022 Jun; 60():101483. PubMed ID: 35367668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.
    Wang J; Zhao H; Zheng L; Zhou Y; Wu L; Xu Y; Zhang X; Yan G; Sheng H; Xin R; Jiang L; Lei J; Zhang J; Chen Y; Peng J; Chen Q; Yang S; Yu K; Li D; Xie Q; Li Y
    Theranostics; 2021; 11(10):5045-5060. PubMed ID: 33754043
    [No Abstract]   [Full Text] [Related]  

  • 33. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression.
    Huang J; Qiu M; Wan L; Wang G; Huang T; Chen Z; Jiang S; Li X; Xie L; Cai L
    Cell Physiol Biochem; 2018; 45(4):1690-1699. PubMed ID: 29490293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines.
    Asada N; Tanaka Y; Hayashido Y; Toratani S; Kan M; Kitamoto M; Nakanishi T; Kajiyama G; Chayama K; Okamoto T
    In Vitro Cell Dev Biol Anim; 2003; 39(7):321-8. PubMed ID: 14753849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis.
    Chen Z; Xie B; Zhu Q; Xia Q; Jiang S; Cao R; Shi L; Qi D; Li X; Cai L
    Int J Med Sci; 2013; 10(13):1868-75. PubMed ID: 24324363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of Fibroblast Growth Factor 19 Is Associated with the Initiation of Colorectal Adenoma.
    Wang D; Zhang J; Li Z; Han J; Gao Y; Chen M; Li Y
    Dig Dis; 2019; 37(3):214-225. PubMed ID: 30517925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
    Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
    Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
    Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
    J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
    Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
    J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
    French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
    PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.